NW024-1 / Chipscreen - LARVOL DELTA

NW024-1, a novel ALPP/ALPPL2-targeting antibody drug conjugate with a topoisomerase 1 inhibitor payload, demonstrates potent antitumor efficacy (AACR 2026) - "NW024-1 is a novel ADC exhibiting a favorable profile and potent antitumor efficacy. These findings highlight its promising therapeutic potential for ALPP-expressing tumors and support its further advancement into clinical investigation."

ADC • Clinical • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALPG • ALPL • ALPP